News Center

VCU Massey Cancer Center has formed a strategic partnership with OncLive^® to give healthcare professionals and patients direct, timely access to important oncology research and clinical practice news from Massey and more than 30 other leading cancer centers, nursing schools and physician groups around the country via OncLive’s publications.

The collaboration between OncLive’s editorial and marketing teams and Massey Cancer Center will focus on news about the center’s advances in research and treatment. Massey is particularly committed to quickly turning its research discoveries into improved cancer treatment, prevention and detection. Its research includes work around cancer cell signaling, cancer molecular genetics, developmental therapeutics, radiation biology and cancer prevention and control.

Researchers at Massey recently discovered a novel chemotherapy combination that is particularly toxic to leukemia and lymphoma cells. The center is the first in Virginia to perform next generation DNA sequencing for precision cancer treatment and also the only one in Richmond to offer Interleuken-2 therapy, which stimulates the body’s immune system to kill cancer cells, for the treatment of metastatic melanoma and metastatic renal cell carcinoma.

“OncLive’s coverage of Massey’s research will help advance the center’s commitment to putting its research discoveries into practice as soon as possible,” said Mike Hennessy Jr., president of Intellisphere Oncology and Healthcare Specialty Group, part of the Plainsboro, N.J.-based Michael J. Hennessy Associates, Inc. (MJH) family of businesses, which includes OncLive. “We’ll also be able to share news of other Massey efforts, such as its investigation into the effects of the Affordable Care Act on cancer survivors.”

VCU Massey Cancer Center is one of 68 among 1,500 total cancer centers in the United States to earn National Cancer Institute designation, which it received in 1975 to help lead and shape the country’s cancer research efforts. It’s also the largest provider of bone marrow transplants in the state of Virginia, an internationally recognized pioneer in providing palliative care for cancer patients and the chronically ill, and a leader in translating research discoveries into improved treatments and advances in cancer prevention and control.

“We run one of the largest cancer clinical trial programs in Virginia,” said Gordon D. Ginder, M.D., director of VCU Massey Cancer Center. “We look forward to working with OncLive to share news about our research, the advances we make in patient care and all of our other contributions in the fight against cancer.”

VCU Massey Cancer Center joins more than 40 other leading cancer centers, nursing schools and physician groups around the country in partnering with OncLive.

Hennessy added, “The Strategic Alliance Partnership program serves everyone committed to fighting cancer. When we work together and share our knowledge broadly, we are better armed to improve our efforts to overcome this devastating disease.”

Written by: Jenny Owen